Nutra Pharma Corp Stock Price To Earnings To Growth
NPHC Stock | USD 0.0002 0.00 0.00% |
Nutra Pharma Corp fundamentals help investors to digest information that contributes to Nutra Pharma's financial success or failures. It also enables traders to predict the movement of Nutra Pink Sheet. The fundamental analysis module provides a way to measure Nutra Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nutra Pharma pink sheet.
Nutra |
Nutra Pharma Corp Company Price To Earnings To Growth Analysis
Nutra Pharma's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Nutra Pharma Corp has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
All Next | Launch Module |
Nutra Fundamentals
Return On Asset | -1.13 | |||
Profit Margin | 28.71 % | |||
Operating Margin | (5.58) % | |||
Current Valuation | 10.33 M | |||
Shares Outstanding | 7.6 B | |||
Shares Owned By Insiders | 1.02 % | |||
Shares Owned By Institutions | 0.01 % | |||
Price To Sales | 6.13 X | |||
Revenue | 51.9 K | |||
Gross Profit | 8.47 K | |||
EBITDA | (365.66 K) | |||
Net Income | (769.18 K) | |||
Cash And Equivalents | 10.45 K | |||
Total Debt | 517.18 K | |||
Current Ratio | 0.03 X | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (878.09 K) | |||
Target Price | 0.53 | |||
Beta | 0.25 | |||
Market Capitalization | 759.68 K | |||
Total Asset | 301.79 K | |||
Z Score | -2.7 | |||
Net Asset | 301.79 K |
About Nutra Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nutra Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nutra Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nutra Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.ZLAB | Zai Lab | |
ASLE | AerSale Corp | |
ATS | AT S Austria |
Other Information on Investing in Nutra Pink Sheet
Nutra Pharma financial ratios help investors to determine whether Nutra Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nutra with respect to the benefits of owning Nutra Pharma security.